Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03276481 · ClinicalTrials.gov registry record
Prospective Evaluation of Taste Function In Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation
A clinical trial of Multiple Myeloma, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- 47
- Enrollment target
- 1
- Study location
NCT03276481: Completed study of Multiple Myeloma, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03276481 is a study of Multiple Myeloma that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 47 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03276481, a study of Multiple Myeloma, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- 47 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to study taste disturbances on patients with myeloma who received high dose melphalan.
Primary Outcome
The primary objective of this protocol is to evaluate the feasibility of comprehensive chemical gustometry in participants with MM undergoing autologous HCT. Chemical gustometry will be evaluated at baseline and on days -1, 7, 14, 30 and 100.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Oral microbiota assessment
- DIAGNOSTIC_TEST Comprehensive chemical gustometry
- DIAGNOSTIC_TEST Measurement of salivary flow
- BEHAVIORAL Surveys assessing taste disturbances
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2017-08-28 |
| Est. Completion | 2023-07-12 |
What the finished NCT03276481 record still lists
NCT03276481 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 47 participants, a relatively small participant target, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 4 interventions - of which Oral microbiota assessment is the first listed.
NCT03276481 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT03276481 about?
NCT03276481 is a clinical study titled "Prospective Evaluation of Taste Function In Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation". The purpose of this study is to study taste disturbances on patients with myeloma who received high dose melphalan.
What is the current status of trial NCT03276481?
This trial is currently completed. The enrollment target is 47 participants. The study started on 2017-08-28. Estimated completion is 2023-07-12.
What conditions does trial NCT03276481 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT03276481?
The interventions under investigation include: Oral microbiota assessment (DIAGNOSTIC_TEST), Comprehensive chemical gustometry (DIAGNOSTIC_TEST), Measurement of salivary flow (DIAGNOSTIC_TEST), Surveys assessing taste disturbances (BEHAVIORAL).
Who is sponsoring clinical trial NCT03276481?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03276481 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03276481's enrollment target sits among peer trials
47 269th of 438 higher than 170 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
RECRUITING · NA
-
Development of a Research Infrastructure for Understanding and Addressing Multiple Myeloma Disparities
RECRUITING
-
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03313011 · 47 participants
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
- NCT03467516 · 47 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
- NCT03886662 · 47 participants · Phase 1
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- NCT04013802 · 47 participants · Phase 1
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI